FAQ

The Clinical Trial Ranking Report (CTR Report) is a data-driven report that helps predict whether a potential drug target is likely to succeed or fail in clinical development for a specific disease. It uses advanced algorithms to analyze how closely a target is related to both the disease itself and successful treatment patterns.

The report is designed for biotech companies, pharmaceutical researchers, and clinicians who are evaluating new drug targets. It provides early insight into a target’s likelihood of success, helping to prioritize research and development investments.

A drug target is typically a protein in the body that a drug is designed to interact with to treat a disease. Choosing the right target is critical for a drug’s effectiveness and safety.

The CTR Report uses a method called Spectra Target Ranking, which evaluates each target based on how closely it is connected to disease-related genes and how similar it is to proteins affected by successful treatments. This combined score gives a probability of the target’s success.

Proximity shows how closely a target is linked to genes known to cause the disease. Selectivity measures how similar the target’s biological effects are to those of known successful treatments. Targets that score high on both are more likely to be effective.

The human interactome is like a map of all known interactions between proteins in our body. It helps scientists understand how diseases spread through these networks and which proteins might be good targets for treatment.

The CTR Report framework uses three modules: Genotype Module: Genes that are genetically linked to the disease. Phenotype Module: Genes that are expressed differently in people with the disease. Treatment Module: Proteins that, when affected by a drug, help return gene expression to a healthy state.
Together, these modules help identify promising drug targets.

It means that based on the target’s network properties and historical data from other drugs and their targeted proteins, the model can rank and predict which drugs targeting this protein are likely to succeed or fail in clinical trials.

No. The CTR Report does not evaluate specific drug compounds—it evaluates the targets those drugs aim for. It helps determine if a target is promising before significant time and money is spent on drug development.

The CTR Report is based on real-world drug success and failure data. It provides a statistically backed estimate that helps reduce risk and guide better decision-making in early drug discovery.

The CTR Report utilizes the spectra platform and its ability to rank targets. The spectra ranking algorithm integrates genetic data, gene expression profiles, protein-protein interactions, perturbation, and other experimental data.

We are constantly updating the disease areas that are covered by the CTR Report.Please reach out to us to see if we can provide you the precise CTR Report you need.